Komori
Cuorips (4894) · InitiativeRaisedLatest Earnings presentation (2026-08-13): "Advanced"

Expansion of the Cell Culture Processing Facility

First written in FY2023. 5 of 9 entries say "Advanced", first in 2026-05-15. Latest entry: 2026-08-13.

9entries
4years
5from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023SoftenedFY2024AdvancedFY2025 – 2026-08-132023: 120232024: 120242025: 120252026: 62026
Same theme, other companies
Expansion of Cell Culture and Processing Facilities and CDMO Manufacturing InfrastructureA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2026RaisedAnnual report

    「CLiC-1 cell-culture processing facility 600 — Subsidies and internal funds March 2027 July 2027 Nakanoshima Qross pilot-scale plant 560 10 Subsidies and internal funds January 2026 December 2026」

    In addition to the previous cell-culture processing facility plan, the company disclosed a ¥600 million CLiC-1 plan and a ¥560 million pilot-scale plant plan at Nakanoshima Qross, expanding the scope and amount of capital investment.
  4. FY2025RaisedAnnual report

    「Cell-culture processing facility 500 — Equity-financing proceeds August 2025 January 2026」

    For the new cell-culture processing facility, planned investment increased from ¥300 million to ¥500 million, with work scheduled to begin in August 2025 and finish in January 2026.
  5. FY2024SoftenedAnnual report

    「Cell-culture processing facility 300 — Equity-financing proceeds April 2025 April 2026」

    The planned investment of ¥300 million was maintained, but the scheduled start was postponed from January 2024 to April 2025 and the scheduled completion from March 2025 to April 2026.
  6. FY2023First statedAnnual report

    「Cell-culture processing facility 300 — Equity-financing proceeds January 2024 March 2025」

    Planned total investment was ¥300 million, with work scheduled to begin in January 2024 and completion scheduled for March 2025. The funding source was equity-financing proceeds.
Moved together

"Obtained manufacturing and marketing approval for human iPS cell-derived cardiac muscle cell sheets and their commercialization" moved the same way as this thread, in the same document, in 6 of its 9 moves.

666665★123456
  1. ★This thread
  2. 1Obtained manufacturing and marketing approval for human iPS cell-derived cardiac muscle cell sheets and their commercialization6×
  3. 2Approval obtained for a myocardial cell sheet in the United States and Europe, with expansion of sales regions6×
  4. 3Joint development of catheter-based cell transplantation therapy6×
  5. 4Establishment of Manufacturing and Marketing Licensing, Sales and Distribution, and Information-Provision Systems6×
  6. 5Drug repositioning of endogenous regenerative factor inducers6×
  7. 6Expanding the one-stop CDMO business using CLiC-15×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Cuorips yet. It last moved in the Earnings presentation of 2026-08-13: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expansion of the Cell Culture Processing Facility | Cuorips Inc. (4894) | Komori